Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor behavior

Pituitary

Volumn 16, Issue 3, 2013, Pages 386-392

  Akinci, Hakan ^a   Kapucu, Aysegul ^b   Dar, Kadriye Akgun ^b   Celik, Ozlem ^a   Tutunculer, Banu ^a   Sirin, Gozde ^c   Oz, Buge ^a   Gazioglu, Nurperi ^a   Ince, Haluk ^c   Aliustaoglu, Süheyla ^c   Kadioglu, Pinar ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Endokrinoloji Metabolizma Ve Diyabet Bilim Dali ^*  (Turkey)

Author keywords

Aggressiveness; Aromatase; Invasion; Prolactinoma

Indexed keywords

AROMATASE; ESTROGEN RECEPTOR BETA;

ADENOMECTOMY; ADULT; ARTICLE; AUTOPSY; CARCINOGENESIS; CONTROLLED STUDY; ENDOCRINE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; SEX DIFFERENCE; TUMOR INVASION; TUMOR REGRESSION; TUMOR RESISTANCE;

EID: 84881375719     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0436-2     Document Type: Article

References (31)

1. Freeman ME, Kanyicska B, Lerant A et al (2000) PRL: structure, function, and regulation of secretion. Physiol Rev 80(4):1523-1631
2. Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67-99
3. Sasano H, Takahashi K, Satoh F, Nagura H, Harada N (1998) Aromatase in the human central nervous system. Clin Endocrinol (Oxf) 48:325-329
4. Kadioglu P, Oral G, Sayitoglu M, Erensoy N, Senel B, Gazioglu N, Sav A, Cetin G, Ozbek U (2008) Aromatase cytochrome P450 enzyme expression in human pituitary. Pituitary 11:29-35
5. Xu RK, Wu XM, Di AK, Xu JN, Pang CS, Pang SF (2000) Pituitary prolactin-secreting tumor formation: recent developments. Biol Signals Recept 9:1-20
6. Spady TJ, Harvell DME, Snyder MC, Pennington KL, McComb RD, Shull JD (1998) Estrogen-induced tumorigenesis in the Copenhagen rat: disparate susceptibilities to development of prolactin-producing pituitary tumors and mammary carcinomas. Cancer Lett 124:95-103
7. Gottesfeld Z, Liehr JG (1987) Chronic exposure to random restraint stress retards the development of estrogen-induced pituitary prolactinoma in rats. Neurosci Lett 80:44-48
8. Carretero J, Burks DJ, Vazquez G, Rubio M, Hernandez H, Bodego P, Vazquez R (2002) Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats. Pituitary 5:5-10
9. Asscheman H, Gooren LJ, Assies J, Smits JP, de Slegte R (1988) Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clin Endocrinol (Oxf) 28(6):583-588
10. Prager D, Braunstein GD (1995) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 24:1-14
11. Garcia MM, Kapcala LP (1995) Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 18(6):450-455
12. Prior JC, Cox TA, Fairholm D, Kosthashuk E, Nugent R (1987) Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J Clin Endocrinol Metab 64:391-394
13. Gillam MP, Middler S, Freed DJ, Molitch M (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87:4447-4451
14. Sodi R, Fikri R, Diver M, Ranganath L, Vora J (2005) Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature. Ann Clin Biochem 42:153-159
15. Heidari Z, Hosseinpanah F, Shirazian N (2010) Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Pract 16:669-672
16. Lv H, Li C, Gui S, Zhang Y (2011) Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender. J Endocrinol Invest. PMID 21422801 (epub ahead of print)
17. Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143-153
18. Detre S, Saccani Jotti G, Dowsett M (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876-878
19. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273-288
20. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089-3099
21. Fideleff HL, Boquete HR, Suarez MG, Azaretzky M (2009) Prolactinoma in children and adolescent. Horm Res 72:197-205
22. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99-106
23. Ma W, Ikeda H, Yoshimoto T (2002) Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Cancer 95:258-266
24. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF, Meyer FB, Kuroki T, Riehle DL, Laws ER (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341
25. Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, Lin C, Zeng YJ, Zhuge QC (2010) Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior. J Neurooncol 99(1):25-32
26. Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD (2009) Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89(2):163-170
27. Cristina C, Diaz-Torga GS, Goya RG, Kakar SS, Perez-Millan MI, Passos VQ, Giannella-Neto D, Bronstein MD, Becu-Villalobos D (2007) PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Mol Cancer 6:4
28. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84(2):761-767
29. Burdman JA, Pauni M, Heredia Sereno GM, Bordón AE (2008) Estrogen receptors in human pituitary tumors. Horm Metab Res 40(8):524-527
30. Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER (1999) Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1:91-98
31. Zafar M, Ezzai S, Raymyar L, Pan N, Smyth HS, Asa SL (1995) Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. J Clin Endocrinol Metab 80:3621-3627